藥明生物、信達生物、百濟神州及三大在線醫療股漲9.5%-16% 北京抗原試劑盒供不應求
據報北京抗原試劑盒供不應求,藥店已加大訂貨量。三大在線醫療股京東健康(06618.HK)、平安好醫生(01833.HK)及阿里健康(00241.HK)升幅擴至11%-16%,後者跑贏高見9.96元,創逾一年高。此外,信達生物(01801.HK)及百濟神州(06160.HK)也急漲近11%,報30.6元及120.25元。
藥明康德(02359.HK)、康方生物(09926.HK)、再鼎醫藥-B(09688.HK)及藥明生物(02269.HK)也升逾5%-9%,後者最強報55.65元,急漲9.5%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.